Trump announces that China wants to return to negotiations and four other news


1. Trump says China wants to return to the negotiating table to end the trade war. The American president, Donald Trump, announced Monday that his Government has received a communication from the chinese authorities saying they are willing to return to the negotiating table to discuss a trade agreement. Trump has stressed for a brief statement on one of the margins of the G7 summit with his Egyptian counterpart, Abdelfatah al Sisi.

2. The yuan weakens again against the dollar until February 2008 lows. The Chinese yuan has fallen again this Monday to a new low since 2008, in the middle of Worsening trade war between China and the United States, which has also caused strong declines in the Chinese stock exchanges: the Hong Kong parquet already registered increases higher than 3% at the end of its session.

3. The average pension of the self-employed is still 37% lower than that of employed persons. Within the total pensions, the average benefit of the self-employed has grown in the last decade by 29.7% compared to the 21.24% increase in the pension average of the general regime. What supposes an average increase to the year of 3%. The average self-employed pension is, at July 31, 2019, 686 euros and 157.24 euros higher than the average self-employed pensions in the same month of 2009, according to ATA.

4. The price of gold is set at highs in April 2013 due to commercial tensions. Gold reappears as a refuge value in the face of the persistence of the trade war between the United States and China. The golden metal has not lost any appeal to retain the most "fearful" capital. In itself, its price has risen to levels in April 2013 after reaching $ 1,528 and has continued to rise.

5.The Spanish pharmacist PharmaMar rises strongly in the stock market after a new agreement on Yondelis. PharmaMar shares bounce strongly on the stock market to around 4%. its price above 2.10 euros per title After having informed the market that it has signed a new license agreement with Janssen whereby this company will have the exclusive right of sale and distribution of its Yondelis anti-tumor drug in the United States.


Source link